Why the study?
Is there a therapeutic window for neuroleptic plasma concentrations to optimize clinical response and minimize side effects?
Is there a therapeutic window for neuroleptic plasma concentrations to optimize clinical response and minimize side effects?
A review of the literature suggests a potential therapeutic window for haloperidol plasma concentrations, though definitive proof is lacking.
Does not support routine haloperidol plasma monitoring; leaves open existence of a therapeutic window pending prospective trials.
There is much interest in finding a therapeutic window for commonly used neuroleptics so that dosage can be individualized and side effects minimized. The authors review specific requirements of good study design and survey the literature that has investigated the relationship between therapeutic response and plasma concentrations of neuroleptics. The evidence from a number of fixed-dose haloperidol studies suggests, but does not yet prove, the existence of a therapeutic window for this compound.
No takes yet. Share an insight, caveat, or question.
Sramek et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: